Health & Saf. Code, § 127694 · Chapter 10. California Affordable Drug Manufacturing Act of 2020
Health & Saf. Code, § 127694
Text — As published in the Legislative Counsel's database, tables dated October 18, 2026 (pubinfo_2025.zip)
(a) On or before December 31, 2023, CHHSA shall submit a report to the Legislature that assesses the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price. The report shall include an analysis of governance structure options for manufacturing functions, including chartering a private organization, a public-private partnership, or a public board of directors.
(b) This section shall only go into effect if the Legislature appropriates funds for this purpose in the annual budget.
(c) The report shall be submitted in compliance with Section 9795 of the Government Code.
(d) This section shall remain in effect only until January 1, 2028, and as of that date is repealed.
Notes and commentary — not statutory text
History
Amended by Stats. 2022, Ch. 47, Sec. 22. (SB 184) Effective June 30, 2022. Repealed as of January 1, 2028, by its own provisions.
Source of truth
- Edition
- As published in the Legislative Counsel's database, tables dated October 18, 2026 (pubinfo_2025.zip)
- Official file
- https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=HSC§ionNum=127694.
- Text hash
- sha256 0384bac0881513e314bb1780eb1400cde65b77c2280120c0279375dbce416497
- Composed by
- compose_ca.py 2026-10-22: the Legislative Counsel's CAML content files read by a tokenizer (caml_readers.reader_a); an independent xml.etree reading (caml_readers.reader_b) agrees on every section
This section cites
Provisions in this library that the text above cites, as it prints each citation. A range cited as “ss. 61.13-61.16” links its first and last provisions.
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.